EUCTR2013-000684-85-NL进行中（未招募）1 期
A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancerpatients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- TESARO Inc.
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed HER2-negative metastatic or
- •locally advanced breast cancer that is not amenable to resection or radiation with curative intent.
- •2. Female and male patients age at least 18 years.
- •3. Patients with a deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation may be enrolled into the study and randomized based on either local or central laboratory testing of BRCA status (Myriad Genetic Laboratories, Salt Lake City, UT, USA). On- study central confirmation of BRCA status will be performed for those patients who were enrolled based on either a previous Myriad test or a local test. If after inclusion, based on a local test result or a previously done Myriad test, a patient turns out not to have a germline BRCA mutation per central laboratory results (Myriad Genetic Laboratories, Salt Lake City, UT, USA) the patient can still continue on study based on his/her physician discretion and his/her own preference.
- •4. Measurable disease by RECIST v1.1 or non- measurable disease that is clinically evaluable (except sclerotic-only bone disease; bone-only disease that has a lytic component is allowed).
- •5. Patients must not have symptomatic uncontrolled brain metastases To be considered controlled, central nervous system (CNS) disease must have undergone treatment (whole brain radiation, radiosurgery or equivalent) at least 1 month previously and the patient has no new or progressive signs or symptoms related to the CNS disease, and are off steroid therapy two weeks.
- •6. Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer (not including adjuvant or neo-adjuvant therapy); patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within 12 months of (neo-)adjuvant cytotoxic therapy .
- •7. Prior therapy should have included a taxane and/ or anthracycline (unless contraindication to those) in the neoadjuvant, adjuvant, or advanced/metastatic setting.
- •a. Hormone receptor positive patients must also have hormone resistant disease; either relapsed while on adjuvant endocrine treatment or within one year of completing adjuvant endocrine treatment, or progression on at least one line of endocrine treatment for advanced cancer.
- •8. Patients must not have received anticancer chemotherapy, radiotherapy (including palliative radiotherapy), hormonal therapy, biological therapy, or any other investigational therapy within 3 weeks prior to the start of study treatment. Patients with persistent toxicity (except alopecia) > grade 1 from prior cancer therapy will also be excluded. Bisphosphonate and denosumab are allowed.
- •9. No prior treatment with a known or putative PARP inhibitor (except iniparib). No other anticancer agent (chemotherapy, hormonal therapy, or other agent) is to be permitted during the course of the study for any patient.
- •10. Patients who have previously received platinum chemotherapy in the metastatic setting are allowed to enroll in the study as long as they did not progress while on or within 8 weeks from the day of the last platinum administration. Patients who received platinum in the (neo-)adjuvant setting are eligible, as long as they relapsed 12 months or more after the last dose of platinum.
- •11. ECOG performance status 0-2 (Appendix G).
- •12. Adequate organ function (assessed within 72 hours prior to the first dose):
- •a. Absolute neutrophil count (ANC) = 1,500 cells/µL
- •b. Platelets = 100,000 ce
排除标准
- •No exclusion criteria are defined per protocol
研究者
相似试验
进行中（未招募）
1 期
A controlled study with Niraparib versus physician's choice in patients with previously-treated, HER2 negative, BRCA mutation-positive breast cancerHER2 negative, BRCA germline mutated breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000684-85-GBTESARO Inc.306
进行中（未招募）
1 期
A controlled study with Niraparib versus physician's choice in patients with previously-treated, HER2 negative, BRCA mutation-positive breast cancerHER2 negative, BRCA germline mutated breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000684-85-PLTESARO Inc.306
进行中（未招募）
1 期
A controlled study with Niraparib versus physician's choice in patients with previously-treated, HER2 negative, BRCA mutation-positive breast cancerEUCTR2013-000684-85-GRTESARO Inc.306
已完成
3 期
A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician*s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer;patientslobular carcinoma10006291breast cancerNL-OMON45039TESARO Inc.16
进行中（未招募）
不适用
A controlled study with Niraparib versus physician's choice in patients with previously-treated, HER2 negative, BRCA mutation-positive breast cancerHER2 negative, BRCA germline mutated breast cancerMedDRA version: 16.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000684-85-ITTESARO Inc.306